PursueCare to Highlight Digital Therapeutics at 2025 Rx Summit in Nashville
PursueCare, a leader in virtual addiction treatment and medication-assisted therapy, is pleased to announce its participation in the 2025 Rx and Illicit Drug Summit, taking place April 21–24 in Nashville, Tennessee. The annual summit is the nation’s foremost event addressing the intersection of healthcare, substance use, and public policy, and brings together key stakeholders from across the continuum of care. As part of the event, PursueCare will be exhibiting at Booth #422, where its team will engage attendees on how digital health innovations are reshaping treatment pathways for substance use disorder (SUD) and opioid use disorder (OUD).
With a strong presence at the summit, PursueCare aims to underscore the transformative role of FDA-authorized digital therapeutics, integrated virtual care models, and pharmacy-based support in closing critical treatment gaps for patients with addiction—especially in underserved or geographically isolated populations.
Introducing FDA-Authorized Digital Therapeutics: RESET® and RESET-O®
At the center of PursueCare’s exhibit will be RESET® and RESET-O®, two pioneering digital therapeutics that are the only FDA-authorized treatments of their kind for SUD and OUD, respectively. These mobile-first, evidence-based platforms are redefining what continuity of care looks like in the modern recovery journey.
Developed using the principles of digital cognitive behavioral therapy (CBT) and contingency management, these tools deliver 24/7 therapeutic engagement through structured interactive modules. They empower patients to build healthier behavioral patterns while maintaining constant visibility into their progress.
RESET® targets patients dealing with SUD who are not currently on opioid replacement therapy, while RESET-O® is designed specifically for patients with OUD receiving buprenorphine-based medication-assisted treatment (MAT). Both therapeutics function as prescription-only software applications, accessible through secure smartphone apps that seamlessly integrate into PursueCare’s telehealth platform.
“These therapeutics are more than digital tools—they are life-changing interventions that fill critical gaps in behavioral support between telehealth appointments,” said Nick Mercadante, Founder and CEO of PursueCare. “They provide patients with tools to manage cravings, track goals, and earn real incentives for progress, ultimately reinforcing positive change.”
A Fully Integrated Model of Virtual Care
The RESET suite of digital therapeutics is just one component of PursueCare’s holistic virtual care model. The company delivers a full spectrum of services, including psychiatric evaluation, therapy, medication management, case coordination, and pharmacy services, all within a HIPAA-compliant digital infrastructure. Patients can enroll, attend appointments, receive prescriptions, and engage in therapy—without ever needing to step foot in a clinic.
This care model is particularly impactful in rural and suburban areas where access to in-person addiction specialists remains limited. By removing barriers related to geography, transportation, stigma, or provider shortages, PursueCare extends specialized care to populations that are often excluded from traditional care networks.
Through the use of secure telehealth sessions, licensed clinicians work with patients to co-develop individualized recovery plans, prescribe evidence-based medications such as Suboxone® (buprenorphine/naloxone) or naltrexone, and track progress longitudinally. The RESET and RESET-O therapeutics complement this care by extending behavior modification support between sessions.
“Addiction is a chronic condition that doesn’t follow a 9-to-5 schedule,” Mercadante noted. “Patients deserve tools that are as dynamic and responsive as the challenges they face. That’s what we’re building at PursueCare.”
PursueCareRx: Redefining Pharmacy Support in Addiction Treatment
In addition to its clinical services, PursueCare will also spotlight its in-house pharmacy arm, PursueCareRx, during the summit. This specialized pharmacy delivers tailored support for patients undergoing MAT, and plays a crucial role in simplifying the often-fragmented prescription experience for both patients and providers.
Led by Joseph Hensley, PharmD, CPGX, BCMAS, PursueCareRx operates with a patient-first philosophy that integrates pharmacy care into the overall recovery process. This is not a conventional pharmacy—it is a vital support hub where every prescription serves as a stepping stone in a larger continuum of healing.
“A pharmacy is more than a place to fill scripts,” said Dr. Hensley. “At PursueCareRx, it’s a mission-driven operation focused on restoring lives. Every bottle we ship, every conversation we have, is a moment where hope is reinforced.”
Key features of PursueCareRx include:
- Comprehensive Medication Fulfillment: PursueCareRx provides fulfillment for MAT drugs, including Suboxone, naltrexone, and related medications that aid in managing co-occurring mental health conditions. The pharmacy accepts prescriptions from both PursueCare clinicians and external providers, whether through telehealth or in-person care settings.
- Discreet Home Delivery: Medications are shipped directly to patients’ homes in confidential packaging, supporting privacy and adherence while eliminating the need for frequent pharmacy visits—an often overlooked barrier for individuals in recovery.
- Support for Healthcare Providers: PursueCareRx assists clinicians with prior authorization processes, prescription monitoring, and compliance with state and federal MAT regulations. This significantly reduces administrative burden, allowing providers to focus on patient care.
- Patient Resources: Online tools for prescription refills, medication updates, and treatment plan adjustments ensure that patients remain empowered and engaged in their own recovery.
Together, PursueCare’s clinical and pharmacy services function as a closed-loop treatment system, providing continuity of care that extends from diagnosis to therapy to medication delivery.
Elevating the Conversation at the Rx and Illicit Drug Summit
The Rx and Illicit Drug Summit—founded in 2012—has grown into the most influential national forum focused on curbing prescription drug misuse and illicit substance abuse. The 2025 summit is expected to convene more than 4,000 stakeholders from diverse sectors, including healthcare, law enforcement, public policy, behavioral health, and academia.
As a presenting organization, PursueCare will contribute to critical conversations around the evolution of addiction care, particularly how technology, digital therapeutics, and coordinated virtual care can help close systemic treatment gaps. Attendees are encouraged to visit Booth #422 to learn more about PursueCare’s model, view demonstrations of the RESET and RESET-O platforms, and explore partnership opportunities.
“Our presence at the Rx and Illicit Drug Summit is about more than visibility—it’s about leadership,” said Mercadante. “We’re here to collaborate with the clinicians, policymakers, advocates, and technologists who share our urgency to rethink how addiction is treated in America.”
About PursueCare
PursueCare is a digital health organization delivering full-spectrum addiction treatment and behavioral health services through secure telehealth platforms. Combining evidence-based clinical care, FDA-authorized digital therapeutics, and specialized pharmacy fulfillment, PursueCare’s model enables individuals to access compassionate, expert care wherever they are. The company operates in multiple states and continues to expand access to life-saving care for individuals struggling with substance use and mental health challenges.
